Nicole off grid last name trial#

Given the high nature of the hurdle, in our original initiating coverage report on KZA, we only gave paxalisib a small chance of returning a positive result from the overall study. Demonstrating efficacy in GBM is an extremely high hurdle as shown by the fact that there is only one approved drug for the disease, temozolomide, and it is only effective in 1/3 of patients.

Nicole off grid last name trial#

The study was an adaptive trial designed to assess the potential of new therapeutics to treat the highly aggressive brain cancer glioblastoma (GBM) in a cost-effective manner. Kazia Therapeutics (KZA) announced yesterday morning that paxalisib did not meet the threshold to move into stage 2 of the GBM AGILE clinical trial (NCT03970447).

Cash on hand of $3.6m (2QįY23) is likely sufficient to fund operations until breakeven is reached.ĭOWNLOAD RESEARCH REPORT Paxalisib Misses AGILE Hurdle, but Very Significant Value Remains Investors Over-React, Smart Ones Will Profit Represents sufficient scale to reach profitability. The company has built a significant new contract pipeline in recent quartersĪnd is targeting c.15,000 subscribers on its platform by Dec 2023, which There is a growing recurring revenueĬomponent built on SaaS-based subscriptions to its platform. The market is very fragmented, with no competitor offering CTQ’sĬTQ’s income stream is non-discretionary and largely funded by federal and Technology innovation and recommendations from the Royal Commission intoĪged Care. Products, driven by the ageing population, rising costs and labour shortages, The health-tech industry enjoys significant tailwinds for assistive living Include falls detection, vital signs monitoring and medication management. Home care, disability care and personal security sectors. (Sofihub) with a portfolio of best-in-class solutions for the global aged care, In response, NickelSearch Managing Director, Nicole Duncan, commented, “Based on these results, it is plausible to suggest that the LCT indicators observed over this area represent one large system.” Shares are trading flat at 4.1 cents.ĬTQ has developed a leading proprietary assistive living technology platform NickelSearch (ASX:NIS) announced Infill soil sampling results over high priority areas of interest confirm significant lithium caesium-tantalum (LCT) anomalies at its 100% owned Carlingup Project near Ravensthorpe in Western Australia. In response, Harvest’s Chief Operating Officer, Linda Shields, said, “The opportunity to work collaboratively and globally within the Five-Eyes defence network is very exciting for us and demonstrates a demand for the capabilities we offer.” Shares are trading 23.08 pr cent higher at 1.6 cents. Harvest Technology Group (ASX:HTG) confirmed that further to its December operations update, it has received both second and third orders for its Nodestream™ technology from its significant Five-Eyes defence customer, in the total amount of approximately $380k AUD with cash received upfront. Shares are trading 38.66 per cent higher at $1.345. The consideration under the Proposal represents an implied value of $1.39 per NPR security and a 43.1% premium to NPR’s last close price of $0.97 on 23 January 2024. Under the proposed merger, BWP will offer to acquire 100% of NPR’s securities via an off market takeover offer for consideration comprising 0.40 BWP units per NPR security. Newmark Property REIT (ASX:NPR) has entered into a merger agreement in relation to a proposed all-scrip merger with BWP Trust.